Cargando…

Theragnostic Radionuclide Pairs for Prostate Cancer Management: (64)Cu/(67)Cu, Can Be a Budding Hot Duo

Prostate cancer (PCa) is one of the preeminent causes of mortality in men worldwide. Theragnostic, a combination of therapy and diagnostic, using radionuclide pairs to diagnose and treat disease, has been shown to be a promising approach for combating PCa. In PCa patients, bone is one of the most co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chhabra, Anupriya, Thakur, Mathew L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687163/ https://www.ncbi.nlm.nih.gov/pubmed/36359312 http://dx.doi.org/10.3390/biomedicines10112787

Ejemplares similares

Theragnostic (64)Cu/(67)Cu Radioisotopes Production With RFT-30 Cyclotron
por: Lee, Jun Young, et al.
Publicado: (2022)

Radionuclide Cisternography with [(64)Cu]Cu-DOTA
por: Greiser, Julia, et al.
Publicado: (2023)

Recent Advances in (64)Cu/(67)Cu-Based Radiopharmaceuticals
por: Krasnovskaya, Olga O., et al.
Publicado: (2023)

Harnessing (64)Cu/(67)Cu for a theranostic approach to pretargeted radioimmunotherapy
por: Keinänen, Outi, et al.
Publicado: (2020)

Cyclotron-Based Production of (67)Cu for Radionuclide Theranostics via the (70)Zn(p,α)(67)Cu Reaction
por: Brühlmann, Santiago Andrés, et al.
Publicado: (2023)

Cyclotron-based production of the theranostic radionuclides $^{67}$Cu and $^{47}$Sc
por: Pupillo, G, et al.
Publicado: (2019)

An abbreviated therapy-dosimetric equation for the companion diagnostic/therapeutic [(64/67)Cu]Cu-SARTATE
por: Laffon, Eric, et al.
Publicado: (2021)

Comparison of the Effects of DOTA and NOTA Chelators on (64)Cu-Cudotadipep and (64)Cu-Cunotadipep for Prostate Cancer
por: Lee, Inki, et al.
Publicado: (2023)

Detection and therapy of neuroblastoma minimal residual disease using [(64/67)Cu]Cu-SARTATE in a preclinical model of hepatic metastases
por: Dearling, Jason L. J., et al.
Publicado: (2021)

Optimisation of clinical SPECT imaging with 155Tb for theragnostic radionuclide therapy
por: Cocolios, Thomas Elias, et al.
Publicado: (2016)

(64)Cu-ATSM/(64)Cu-Cl(2) and their relationship to hypoxia in glioblastoma: a preclinical study
por: Pérès, Elodie A., et al.
Publicado: (2019)

An international multi-center investigation on the accuracy of radionuclide calibrators in nuclear medicine theragnostics
por: Saldarriaga Vargas, Clarita, et al.
Publicado: (2020)

Is (70)Zn(d,x)(67)Cu the Best Way to Produce (67)Cu for Medical Applications?
por: Nigron, Etienne, et al.
Publicado: (2021)

[(64)Cu]Cu-DOTATATE PET metrics in the investigation of atherosclerotic inflammation in humans
por: Jensen, Jacob K., et al.
Publicado: (2022)

Imaging Neurotensin Receptor in Prostate Cancer With (64)Cu-Labeled Neurotensin Analogs
por: Deng, Huaifu, et al.
Publicado: (2017)

(64)Cu-based Radiopharmaceuticals in Molecular Imaging
por: Zhou, Yeye, et al.
Publicado: (2019)

(64)Cu-Labeled Inhibitors of Prostate-Specific Membrane Antigen for PET Imaging of Prostate Cancer
por: Banerjee, Sangeeta Ray, et al.
Publicado: (2014)

A feasibility study of the therapeutic application of a mixture of (67/64)Cu radioisotopes produced by cyclotrons with proton irradiation
por: De Nardo, Laura, et al.
Publicado: (2022)

Aptamers as Theragnostic Tools in Prostate Cancer
por: Cruz-Hernández, Carlos David, et al.
Publicado: (2022)

Radiation Dosimetry of Theragnostic Pairs for Isotopes of Iodine in IAZA
por: Jans, Hans-S., et al.
Publicado: (2022)

Magnetic moment of $^{67}$Ni and $^{67}$Ni $\rightarrow ^{67}$Cu $\beta$-decay
por: Ríkovská, J, et al.
Publicado: (1996)

Synthesis and evaluation of (64)Cu-radiolabeled NOTA-cetuximab ((64)Cu-NOTA-C225) for immuno-PET imaging of EGFR expression
por: Xu, Xiaoxia, et al.
Publicado: (2019)

Copper Coordination Chemistry of Sulfur Pendant Cyclen Derivatives: An Attempt to Hinder the Reductive-Induced Demetalation in (64/67)Cu Radiopharmaceuticals
por: Tosato, Marianna, et al.
Publicado: (2021)

(64)Cu-ATSM and (18)FDG PET uptake and (64)Cu-ATSM autoradiography in spontaneous canine tumors: comparison with pimonidazole hypoxia immunohistochemistry
por: Hansen, Anders E, et al.
Publicado: (2012)

The somatostatin receptor 2 antagonist (64)Cu-NODAGA-JR11 outperforms (64)Cu-DOTA-TATE in a mouse xenograft model
por: Rylova, Svetlana N., et al.
Publicado: (2018)

Radiobiological Characterization of (64)CuCl(2) as a Simple Tool for Prostate Cancer Theranostics
por: Guerreiro, Joana Fernandes, et al.
Publicado: (2018)

(67)Cu Production Capabilities: A Mini Review
por: Mou, Liliana, et al.
Publicado: (2022)

Prostate-specific membrane antigen-mediated theragnostics in prostate cancer
por: Jeong, Seung-hwan, et al.
Publicado: (2021)

Comparison between Three Promising ß-emitting Radionuclides, (67)Cu, (47)Sc and (161)Tb, with Emphasis on Doses Delivered to Minimal Residual Disease
por: Champion, Christophe, et al.
Publicado: (2016)

Effect of intratumoral administration on biodistribution of (64)Cu-labeled nanoshells
por: Xie, Huan, et al.
Publicado: (2012)

Integrated (64)Cu therapy for the peritoneal dissemination of gastrointestinal cancer
por: Kurihara, Hiroaki
Publicado: (2018)

Pilot Study of (64)Cu(I) for PET Imaging of Melanoma
por: Jiang, Lei, et al.
Publicado: (2017)

(64)Cu-DOTATOC PET-CT in Patients with Neuroendocrine Tumors
por: Mirzaei, Siroos, et al.
Publicado: (2019)

Effect of Liraglutide on Vascular Inflammation Evaluated by [(64)Cu]DOTATATE
por: Zobel, Emilie H., et al.
Publicado: (2021)

Tissue acidosis does not mediate the hypoxia selectivity of [(64)Cu][Cu(ATSM)] in the isolated perfused rat heart
por: Baark, Friedrich, et al.
Publicado: (2019)

Molecular Dynamics Study of the Nanoindentation Behavior of Cu(64)Zr(36)/Cu Amorphous/Crystalline Nanolaminate Composites
por: Wu, Wen-Ping, et al.
Publicado: (2021)

Development of an automated production process of [(64)Cu][Cu (ATSM)] for positron emission tomography imaging and theranostic applications
por: Liu, Tengzhi, et al.
Publicado: (2022)

Intrathecal [(64)Cu]Cu-albumin PET reveals age-related decline of lymphatic drainage of cerebrospinal fluid
por: Sarker, Azmal, et al.
Publicado: (2023)

In vitro and in vivo characterization of [(64)Cu][Cu(elesclomol)] as a novel theranostic agent for hypoxic solid tumors
por: Liu, Tengzhi, et al.
Publicado: (2023)

Copper-67-Labeled Bombesin Peptide for Targeted Radionuclide Therapy of Prostate Cancer
por: Huynh, Truc T., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sgso96a8tdmfb7ahdh0jhf4mb7